EP
ARCT icon

Essential Partners’s Arcturus Therapeutics ARCT Stock Holding History

Essential Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54K Buy
824
+488
+145% +$3.85K ﹤0.01% 1501
2026
Q1 		$2.59K Buy
336
+333
+11,100% +$2.43K ﹤0.01% 1897
2025
Q4 		$18 Buy
+3
New +$32 ﹤0.01% 2722

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Essential Partners's ARCT Position: Q2 2026 in Review

Essential Partners increased its Arcturus Therapeutics (ARCT) stake by 145% in Q2 2026, buying an estimated $3.85K and bringing the position to 824 shares worth $5.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

Essential Partners first reported a position in ARCT in Q4 2025 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Essential Partners held 824 shares of Arcturus Therapeutics worth $5.54K as of Q2 2026.
  • Essential Partners bought 488 Arcturus Therapeutics shares in Q2 2026, an estimated $3.85K.
  • Arcturus Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1501 holding.
  • Essential Partners first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.